CD19 and diffuse large B-cell lymphoma: In the ongoing ZUMA-6 trial, R/R DLBCL patients are treated with an anti-CD19 CAR T-cell regimen, followed by 4 doses of atezolizumab (1200 mg/dose) as an IV infusion every 21 days (NCT02926833).